# Tocilizumab in Active Moderate-severe Graves' Orbitopathy

> **NCT04876534** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 64 (estimated)

## Conditions studied

- Graves Ophthalmopathy

## Interventions

- **DRUG:** Tocilizumab 20 Mg/mL Intravenous Solution
- **DRUG:** MethylPREDNISolone Injectable Solution

## Key facts

- **NCT ID:** NCT04876534
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-18
- **Primary completion:** 2022-12-18
- **Final completion:** 2023-12-18
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2022-08-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876534, "Tocilizumab in Active Moderate-severe Graves' Orbitopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04876534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*